Impact of targeting insulin-like growth factor signaling in head and neck cancers

Growth Hormone and IGF Research

Volumn 23, Issue 5, 2013, Pages 135-140

  Limesand, Kirsten H ^a   Chibly, Alejandro Martinez ^a   Fribley, Andrew ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical outcomes; Head and neck cancer; IGF inhibition

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GANITUMAB; GEFITINIB; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; METFORMIN; MM 141; MONOCLONAL ANTIBODY; PANITUMUMAB; PROTEIN P53; RAPAMYCIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

BODY MASS; BREAST CANCER; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; DISEASE FREE SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OBESITY; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

AKT; AMP-ACTIVATED PROTEIN KINASE; AMPK; CLINICAL OUTCOMES; EGF; EGFR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HNSCC; IGF; IGF INHIBITION; IGF-1-R; IGFBP; INSULIN RECEPTOR SUBSTRATE; INSULIN-LIKE GROWTH FACTOR; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN; INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR; IRS; MAMMALIAN TARGET OF RAPAMYCIN; MAPK; MITOGEN-ACTIVATED PROTEIN KINASES; MTOR; OCSCC; ORAL CAVITY SQUAMOUS CELL CARCINOMA; PHOSPHATIDYLINOSITOL 3-KINASE; PI3K; PROTEIN KINASE B, PKB;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MOLECULAR TARGETED THERAPY; OBESITY; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84882914592     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2013.06.001     Document Type: Review

References (71)

1. Le Roith D. The insulin-like growth factor system. Exp. Diabesity Res. 2003, 4:205-212.
2. Gao Y., Katki H., Graubard B., Pollak M., Martin M., Tao Y., Schoen R.E., Church T., Hayes R.B., Greene M.H., et al. Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. Int. J. Cancer 2012, 131:E105-E113.
3. Ewing G.P., Goff L.W. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin. Colorectal Cancer 2010, 9:219-223.
4. Lahti E.I., Knip M., Laatikainen T.J. Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer 1994, 74:618-624.
5. Furstenberger G., Morant R., Senn H.J. Insulin-like growth factors and breast cancer. Onkologie 2003, 26:290-294.
6. Lukanova A., Lundin E., Toniolo P., Micheli A., Akhmedkhanov A., Rinaldi S., Muti P., Lenner P., Biessy C., Krogh V., et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int. J. Cancer 2002, 101:549-554.
7. Rohrmann S., Grote V.A., Becker S., Rinaldi S., Tjonneland A., Roswall N., Gronbaek H., Overvad K., Boutron-Ruault M.C., Clavel-Chapelon F., et al. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Br. J. Cancer 2012, 106:1004-1010.
8. Kim Y.H., Sumiyoshi S., Hashimoto S., Masago K., Togashi Y., Sakamori Y., Okuda C., Mio T., Mishima M. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer. Clin. Lung Cancer 2012, 13(5):385-390.
9. Li B.D., Khosravi M.J., Berkel H.J., Diamandi A., Dayton M.A., Smith M., Yu H. Free insulin-like growth factor-I and breast cancer risk. Int. J. Cancer 2001, 91:736-739.
10. Giovannone B., Scaldaferri M.L., Federici M., Porzio O., Lauro D., Fusco A., Sbraccia P., Borboni P., Lauro R., Sesti G. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab. Res. Rev. 2000, 16:434-441.
11. Cai D., Dhe-Paganon S., Melendez P.A., Lee J., Shoelson S.E. Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. J. Biol. Chem. 2003, 278:25323-25330.
12. Zhang H., Hoff H., Sell C. Insulin-like growth factor I-mediated degradation of insulin receptor substrate-1 is inhibited by epidermal growth factor in prostate epithelial cells. J. Biol. Chem. 2000, 275:22558-22562.
13. Tzatsos A. Raptor binds the SAIN (Shc and IRS-1 NPXY binding) domain of insulin receptor substrate-1 (IRS-1) and regulates the phosphorylation of IRS-1 at Ser-636/639 by mTOR. J. Biol. Chem. 2009, 284:22525-22534.
14. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004, %19(166):213-223.
15. Oliveira J.C., Souza K.K., Dias M.M., Faria M.C., Ropelle E.R., Flores M.B., Ueno M., Velloso L.A., Saad S.T., Saad M.J., et al. Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts. J. Cancer Res. Clin. Oncol. 2008, 134:833-839.
16. Zakikhani M., Blouin M.J., Piura E., Pollak M.N. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res. Treat. 2010, 123:271-279.
17. Hartog H., Wesseling J., Boezen H.M., van der Graaf W.T. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur. J. Cancer 2007, 43:1895-1904.
18. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur. J. Cancer 2000, 36:1224-1228.
19. Diorio C., Pollak M., Byrne C., Masse B., Hebert-Croteau N., Yaffe M., Cote G., Berube S., Morin C., Brisson J. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1065-1073.
20. Baserga R., Peruzzi F., Reiss K. The IGF-1 receptor in cancer biology. Int. J. Cancer 2003, 107:873-877.
21. Sekharam M., Zhao H., Sun M., Fang Q., Zhang Q., Yuan Z., Dan H.C., Boulware D., Cheng J.Q., Coppola D. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res. 2003, 63:7708-7716.
22. Jacobs E.T., Martinez M.E., Alberts D.S., Ashbeck E.L., Gapstur S.M., Lance P., Thompson P.A. Plasma insulin-like growth factor I is inversely associated with colorectal adenoma recurrence: a novel hypothesis. Cancer Epidemiol. Biomarkers Prev. 2008, 17:300-305.
23. Lonn S., Inskip P.D., Pollak M.N., Weinstein S.J., Virtamo J., Albanes D. Glioma risk in relation to serum levels of insulin-like growth factors. Cancer Epidemiol. Biomarkers Prev. 2007, 16:844-846.
24. Cutting C.W., Hunt C., Nisbet J.A., Bland J.M., Dalgleish A.G., Kirby R.S. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int. 1999, 83:996-999.
25. Woodson K., Tangrea J.A., Pollak M., Copeland T.D., Taylor P.R., Virtamo J., Albanes D. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res. 2003, 63:3991-3994.
26. Chen C., Lewis S.K., Voigt L., Fitzpatrick A., Plymate S.R., Weiss N.S. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005, 103:76-84.
27. Rowlands M.A., Holly J.M., Gunnell D., Donovan J., Lane J.A., Hamdy F., Neal D.E., Oliver S., Smith G.D., Martin R.M. Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res. 2012, 72:503-515.
28. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
29. Forastiere A., Koch W., Trotti A., Sidransky D. Head and neck cancer. N. Engl. J. Med. 2001, 345:1890-1900.
30. Sun J.M., Jun H.J., Ko Y.H., Park Y.H., Ahn Y.C., Son Y.I., Baek J.H., Park K., Ahn M.J. Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck. Oral Oncol. 2011, 47:714-719.
31. Oy G.F., Slipicevic A., Davidson B., Solberg F.R., Maelandsmo G.M., Florenes V.A. Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. Int. J. Cancer 2010, 126:350-361.
32. Matuschek C., Rudoy M., Peiper M., Gerber P.A., Hoff N.P., Buhren B.A., Flehmig B., Budach W., Knoefel W.T., Bojar H., et al. Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients. Eur. J. Med. Res. 2011, 16:451-456.
33. Lara P.C., Bordon E., Rey A., Moreno M., Lloret M., Henriquez-Hernandez L.A. IGF-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma. Oral Oncol. 2011, 47:615-619.
34. Wu X., Zhao H., Do K.A., Johnson M.M., Dong Q., Hong W.K., Spitz M.R. Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin. Cancer Res. 2004, 10:3988-3995.
35. Adelstein D.J., Koyfman S.A., El Naggar A.K., Hanna E.Y. Biology and management of salivary gland cancers. Semin. Radiat. Oncol. 2012, 22:245-253.
36. Carboni J.M., Lee A.V., Hadsell D.L., Rowley B.R., Lee F.Y., Bol D.K., Camuso A.E., Gottardis M., Greer A.F., Ho C.P., et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. 2005, 65:3781-3787.
37. Olivo-Marston S.E., Hursting S.D., Lavigne J., Perkins S.N., Maarouf R.S., Yakar S., Harris C.C. Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice. Mol. Carcinog. 2009, 48:1071-1076.
38. Sutherland B.W., Knoblaugh S.E., Kaplan-Lefko P.J., Wang F., Holzenberger M., Greenberg N.M. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res. 2008, 68:3495-3504.
39. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004, 4:579-591.
40. Doyle S.L., Donohoe C.L., Finn S.P., Howard J.M., Lithander F.E., Reynolds J.V., Pidgeon G.P., Lysaght J. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am. J. Gastroenterol. 2012, 107:196-204.
41. McColl K.E. Serum IGF-1 linking visceral obesity with esophageal adenocarcinoma: unconvincing evidence. Am. J. Gastroenterol. 2012, 107:205-206.
42. Chung C.H., Pohlmann P.R., Rothenberg M.L., Burkey B.B., Parker J., Palka K., Aulino J., Puzanov I., Murphy B. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck 2011, 33:1804-1808.
43. Matsumoto F., Valdecanas D.N., Mason K.A., Milas L., Ang K.K., Raju U. The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation. Anticancer. Res. 2012, 32:3029-3035.
44. Beltran P.J., Mitchell P., Chung Y.A., Cajulis E., Lu J., Belmontes B., Ho J., Tsai M.M., Zhu M., Vonderfecht S., et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol. Cancer Ther. 2009, 8:1095-1105.
45. Rosen L.S., Puzanov I., Friberg G., Chan E., Hwang Y.C., Deng H., Gilbert J., Mahalingam D., McCaffery I., Michael S.A., et al. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin. Cancer Res. 2012, 18:3414-3427.
46. Kindler H.L., Richards D.A., Garbo L.E., Garon E.B., Stephenson J.J., Rocha-Lima C.M., Safran H., Chan D., Kocs D.M., Galimi F., et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann. Oncol. 2012, 23(11):2834-2842.
47. Olmos D., Basu B., de Bono J.S. Targeting insulin-like growth factor signaling: rational combination strategies. Mol. Cancer Ther. 2010, 9:2447-2449.
48. Rodon J., DeSantos V., Ferry R.J., Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol. Cancer Ther. 2008, 7:2575-2588.
49. Schmitz S., Kaminsky-Forrett M.C., Henry S., Zanetta S., Geoffrois L., Bompas E., Moxhon A., Mignion L., Guigay J., Knoops L., et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann. Oncol. 2012, 23:2153-2161.
50. American Association for Cancer Research Trial is halted for ganitumab in pancreatic cancer. Cancer Discov. 2012, 2:8290.
51. Rocha R.L., Hilsenbeck S.G., Jackson J.G., VanDenBerg C.L., Weng C., Lee A.V., Yee D. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin. Cancer Res. 1997, 3:103-109.
52. Nagle J.A., Ma Z., Byrne M.A., White M.F., Shaw L.M. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol. Cell. Biol. 2004, 24:9726-9735.
53. Byron S.A., Horwitz K.B., Richer J.K., Lange C.A., Zhang X., Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br. J. Cancer 2006, 95:1220-1228.
54. Luo X., Fan S., Huang W., Zhai S., Ma Z., Li P., Sun S.Y., Wang X. Downregulation of IRS-1 promotes metastasis of head and neck squamous cell carcinoma. Oncol. Rep. 2012, 28:659-667.
55. Morgillo F., Woo J.K., Kim E.S., Hong W.K., Lee H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006, 66:10100-10111.
56. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 2002, 14:381-395.
57. Knowlden J.M., Gee J.M., Barrow D., Robertson J.F., Ellis I.O., Nicholson R.I., Hutcheson I.R. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. Breast Cancer Res. 2011, 13:R93.
58. Knowlden J.M., Jones H.E., Barrow D., Gee J.M., Nicholson R.I., Hutcheson I.R. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for gefitinib ('Iressa') response and resistance. Breast Cancer Res. Treat. 2008, 111:79-91.
59. Mukohara T., Shimada H., Ogasawara N., Wanikawa R., Shimomura M., Nakatsura T., Ishii G., Park J.O., Janne P.A., Saijo N., et al. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Lett. 2009, 282:14-24.
60. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., Rinehart C., Seidel B., Yee D., Arteaga C.L., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 2008, 118:2609-2619.
61. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., Akiyama M., Chauhan D., Munshi N., Gu X., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:540-545.
62. Isebaert S.F., Swinnen J.V., McBride W.H., Haustermans K.M. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81:239-247.
63. Turner B.C., Haffty B.G., Narayanan L., Yuan J., Havre P.A., Gumbs A.A., Kaplan L., Burgaud J.L., Carter D., Baserga R., et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997, 57:3079-3083.
64. Floratou K., Giannopoulou E., Antonacopoulou A., Karakantza M., Adonakis G., Kardamakis D., Matsouka P. Oxidative stress due to radiation in CD34+ hematopoietic progenitor cells: protection by IGF-1. J. Radiat. Res. 2012, 53:672-685.
65. Lugovskoy A., Johnson B., Baum J., Adams S., Tang J., Kohli N., Rennard R., Xu L., Jiao Y., Nilesen U., et al. 11A.D. Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3. Mol. Cancer Ther. 2012, 10. (Abstr.).
66. Baum J., Johnson B., Adams S., Tang J., Kohli N., Rennard R., Sundararajan P., Xu L., Jiao Y., Schoeberl B., et al. MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, blocks ligand-induced signaling and demonstrates antitumor activity. Mol. Cancer Ther. 2012, 72. (Abstr.).
67. Heidegger I., Pircher A., Klocker H., Massoner P. Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol. Ther. 2011, 11:701-707.
68. Perisanidis C., Wrba F., Brandstetter A., Kornek G., Mitchell D., Seemann R., Selzer E., Ewers R., Filipits M. Impact of epidermal growth factor receptor, mesenchymal-epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancer. Br. J. Oral Maxillofac. Surg. 2013, 51:234-240.
69. Guha M. Anticancer IGF1R classes take more knocks. Nat. Rev. Drug Discov. 2013, 12:250.
70. Fidler M.J., Basu S., Buckingham L., Walters K., McCormack S., Batus M., Coon J., Bonomi P. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer. Res. 2012, 32:1705-1710.
71. Robertson J.F., Ferrero J.M., Bourgeois H., Kennecke H., de Boer R.H., Jacot W., McGreivy J., Suzuki S., Zhu M., McCaffery I., et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol. 2013, 14:228-235.